Structural effects of sprifermin in knee osteoarthritis: a post-hoc analysis on cartilage and non-cartilaginous tissue alterations in a randomized controlled trial.

BMC Musculoskelet Disord 2016 07 9;17:267. Epub 2016 Jul 9.

Quantitative Imaging Center (QIC), Boston University School of Medicine, Boston, MA, USA.

Background: A recent publication on efficacy of Sprifermin for knee osteoarthritis (OA) using quantitatively MRI-defined central medial tibio-femoral compartment cartilage thickness as the structural primary endpoint reported no statistically significant dose response. However, Sprifermin was associated with statistically significant, dose-dependent reductions in loss of total and lateral tibio-femoral cartilage thickness. Based on these preliminary promising data a post-hoc analysis of secondary assessment and endpoints was performed to evaluate potential effects of Sprifermin on semi-quantitatively evaluated structural MRI parameters. Aim of the present analysis was to determine effects of sprifermin on several knee joint tissues over a 12 month period.

Methods: 1.5 T or 3 T MRIs were acquired at baseline and 12 months follow-up using a standard protocol. MRIs were read according to the Whole-Organ Magnetic Resonance Imaging Score (WORMS) scoring system (in 14 articular subregions) by four muskuloskeletal radiologists independently. Analyses focused on semiquantitative changes in the 100 μg subgroup and matching placebo of multiple MRI-defined structural alterations. Analyses included a delta-subregional and delta-sum approach for the whole knee and the medial and lateral tibio-femoral (MTFJ, LTFJ), and patello-femoral (PFJ) compartments, taking into account number of subregions showing no change, improvement or worsening and changes in the sum of subregional scores. Mann-Whitney - Wilcoxon tests assessed differences between groups.

Results: Fifty-seven and 18 patients were included in the treatment and matched placebo subgroups. Less worsening of cartilage damage was observed from baseline to 12 months in the PFJ (0.02, 95 % confidence interval (CI) (-0.04, 0.08) vs. placebo 0.22, 95 % CI (-0.05, 0.49), p = 0.046). For bone marrow lesions (BMLs), more improvement was observed from 6 to 12 months for whole knee analyses (-0.14, 95 % CI (-0.48, 0.19) vs. placebo 0.44, 95 % CI (-0.15, 1.04), p = 0.042) although no significant effects were seen from the baseline visit, or in Hoffa-synovitis, effusion-synovitis, menisci and osteophytes.

Conclusions: In this post-hoc analysis cartilage showed less worsening from baseline to 12 months in the PFJ, and BMLs showed more improvement from 6 to 12 months for the whole knee.

Trial Registration: ClinicalTrials.gov identifier: NCT01033994 .

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12891-016-1128-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938999PMC
July 2016
24 Reads

Publication Analysis

Top Keywords

sprifermin knee
12
post-hoc analysis
12
baseline 12 months
12
effects sprifermin
12
12 months pfj
8
cartilage thickness
8
lateral tibio-femoral
8
analysis cartilage
8
knee osteoarthritis
8
bmls improvement
8
sprifermin
5
12 months
5
knee
5
cartilage
5
standard protocol
4
treatment matched
4
12 months follow-up
4
placebo subgroups
4
protocol mris
4
matched placebo
4

References

(Supplied by CrossRef)

K Pavelká et al.
Arch Intern Med 2002

KD Brandt et al.
Arthritis Rheum 2005

JY Reginster et al.
Ann Rheum Dis 2013

H Graverand MP le et al.
Ann Rheum Dis 2013

DJ Hunter et al.
Nat Rev Rheumatol 2011

JL Ellsworth et al.
Osteoarthritis Cartilage 2002

EE Moore et al.
Osteoarthritis Cartilage 2005

LS Lohmander et al.
Arthritis Rheumatol 2014

FW Roemer et al.
Ann Rheum Dis 2013

JH Kellgren et al.
Ann Rheum Dis 1957

F Eckstein et al.
Arthritis Rheumatol 2015

Similar Publications